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Abstract 28 
Angiotensin I-converting enzyme (ACE) inhibitory peptides derived from Spanish dry-29 
cured ham have been examined for their stability during processing and after in vitro 30 
digestion. Peptides preserved almost the same ACE inhibitory activity after applying 31 
diverse heat tretaments (from 50 to 117 ºC), times of processing (from 3 to 60 min) and 32 
simulated in vitro digestion with gastrointestinal proteases. Peptides KAAAAP, 33 
AAPLAP, KPVAAP, IAGRP, and KAAAATP were the most potent peptides with IC50 34 
values ranging from 12.37 μM to 25.94 μM. Peptides IAGRP and PTPVP have also 35 
been identified in the processed sample (6 min at 117 ºC), and in the in vitro digested 36 
sample. This study has shown the high stability of ACE inhibitory peptides derived 37 
from Spanish dry-cured ham against temperature of processing and gastrointestinal 38 
digestion as well as the powerful ACE inhibitory activity of some of the peptides 39 
identified in the Spanish dry-cured ham extract. 40 
 41 
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1. Introduction 46 
Many dietary proteins exert beneficial effects upon human health once released from 47 
their parent protein either by digestive enzymes during gastrointestinal digestion or by 48 
fermentation or ripening during food processing (Korhonen, Pihlanto-Leppala, 49 
Rantamaki & Tupasela, 1998). Bioactive peptides usually range in size from 2 to 50 50 
amino acid residues and can exhibit different activities, such as antimicrobial, 51 
antioxidant, antithrombotic, antihipertensive, inmunomodulatory, and opioid, among 52 
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others (Meisel & Fitzgerald, 2003; Lopez-Fandino, Otte & Van Camp, 2006; Toldrá and 53 
Reig, 2011). Peptides possessing specific biological properties make them potential 54 
ingredients of functional or health-promoting foods since they could reduce the risk of 55 
chronic diseases and promote human health (Hartmann & Meisel, 2007).  56 
The industrial application of these peptides and their incorporation into foods may 57 
affect the functional, nutritional, and biological properties of these peptides (Abdul-58 
Hamid, Bakar & Bee, 2002; Vaslin, Le Guillou, Hannoucene & Saint Denis, 2006; Paul 59 
& Somkuti, 2009). On the other hand, when bioactive peptides are in the digestive tract 60 
after consumption, the activity of gastric enzymes may also affect their biological 61 
activities. In fact once ingested, proteins and peptides are subjected to hydrolysis by 62 
different enzymes such as pepsin, trypsin, or chymotrypsin. Some of the released 63 
peptides may exert a direct function at the gastrointestinal tract, whereas other peptides 64 
can be absorbed and reach target organs and tissues through systemic circulation 65 
(Shimizu, 2004). In previous studies, Escudero, Sentandreu and Toldrá (2010) 66 
demonstrated the generation of ACE inhibitory peptides after gastrointestinal digestion 67 
of pork meat. Moreover, in a recent study, Escudero, Toldrá, Sentandreu, Nishimura 68 
and Arihara (2012) investigated the in vivo antihypertensive activity of three novel 69 
peptides identified in the in vitro digest of pork meat, resulting in a significant decrease 70 
in systolic blood pressure after oral administration to spontaneously hypertensive rats. 71 
Our previous studies demonstrated that Spanish dry-cured ham is a natural source of 72 
peptides that show ACE inhibitory and in vivo antihypertensive activity in 73 
spontaneously hypertensive rats (Escudero, Aristoy, Nishimura, Ariahara & Toldrá, 74 
2012; Escudero, Mora, Fraser, Aristoy & Toldrá, 2013). Since there is a lack of 75 
information related to the influence of food processing and gastrointestinal digestion on 76 
the bioactivity of ACE inhibitory and antihypertensive peptides, the study of the 77 
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bioactive peptides stability during processing and after gastrointestinal digestion as well 78 
as the effects on their ACE inhibitory activity are of great importance. In this study, a 79 
Spanish dry-cured ham extract rich in bioactive peptides showing ACE inhibitory 80 
activity was used to study the impact of heat treatment and in vitro gastrointestinal 81 
digestion on its stability. 82 
2. Materials and methods 83 
2.1 Material and reagents 84 
Dry-cured ham used in this study was a Designation of Origin of Teruel ham (D.O. 85 
Teruel, Spain), with a minimum time of ripening of fourteen months. The population 86 
used for the production of D.O. Teruel are maternal line Landrace and Large White 87 
crossbreds and paternal line purebred Duroc. Angiotensin-converting enzyme (from 88 
rabbit lung) was purchased from Sigma Chemical Co. (St. Louis, Mo., U.S.A). Abz-89 
Gly-p-nitro-phe-pro-OH trifluoroacetate salt was obtained from Bachem AG. 90 
(Bubendorf, Switzerland). Pepsin (from hog stomach) was purchased from Fluka 91 
Chemie Gmbh (Buchs, Switzerland), and pancreatin (from porcine pancreas) was 92 
purchased from Sigma Chemical Co. (St. Louis, Mo., U.S.A). Other chemicals and 93 
reagents used were of analytical grade. 94 
2.2 Peptide extraction 95 
A sample of 100 g of Spanish dry-cured ham were minced and homogenized with 500 96 
mL of 0.01N HCl in a Polytron
®
 (Kinematica, Switzerland) for 5 min. The homogenate 97 
was kept at 4 ºC overnight for decanting, and the supernatant was filtered through a 98 
plastic mesh to retain the biggest pieces and then filtered again through a qualitative 99 
filter paper (Whatman
TM
, UK). After that, the sample was freeze-dried and further 100 
submitted to solid phase extraction using an Oasis
® 
HLB cartridge (35 cc, Waters, 101 
Ireland) in which the peptides were retained and then eluted using methanol-distilled 102 
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water (95:5, v/v). The eluted sample was lyophilized, constituting the starting material 103 
for the subsequent experiments.  104 
2.3 Assay of ACE Inhibitory Activity 105 
 The ACE inhibitory activity of the Spanish dry-cured ham extract (control), processed 106 
sample, processed and further digested sample, and the synthesized peptides was 107 
measured according to the method developed by Sentandreu and Toldrá (2006).  This 108 
assay is based on the ability of ACE to hydrolyze the internally quenched fluorescent 109 
substrate o-aminobenzoylglycyl-p-nitro-L-phenylalanyl-L-proline (Abz-Gly-Phe-(NO2)-110 
Pro). A sample solution (50 μL dry-cured ham extract or synthesized peptide) was 111 
mixed with 50 μL of 150 mM Tris-base buffer (pH 8.3) containing 3 mU/mL of ACE, 112 
and the mixture was preincubated for 10 min at 37 ºC.  The reaction was initiated by the 113 
addition of 200 μL of 150 mM Tris-base buffer (pH 8.3) containing 1.125 M NaCl and 114 
10 mM Abz-Gly-Phe- (NO2)-Pro, which was preincubated again for 10 min at 37 ºC.  115 
Finally, the reaction mixture was then incubated for 45 min at 37 ºC.  The generation of 116 
fluorescence due to the release of o-aminobenzoylglycine (Abz-gly) by the action of 117 
ACE was measured using excitation and emission wavelengths of 355 and 405 nm, 118 
respectively.  ACE inhibition of control, processed sample, and processed and 119 
subsequently digested sample is expressed as relative ACE inhibitory percentage and 120 
the ACE inhibition of synthesized peptides is expressed as IC50. The IC50 value is the 121 
concentration associated with 50% ACE inhibition in the reaction mixture. The 122 
experiments were performed by triplicate. 123 
2.4 Stability of dry-cured ham ACE inhibitory peptides 124 
Spanish dry-cured ham ACE inhibitory peptide solutions (5 mg/mL) were incubated at 125 
various temperatures, 50, 72, 90 and 117 ºC for 6 min. On the other hand, the peptide 126 
solutions were also incubated at 117ºC at different times 3, 6, 15, 30 and 60 min. All 127 
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solutions were taken to room temperature before the ACE inhibitory activity analysis, 128 
which was determined as described above. Triplicate assays were performed for each 129 
sample. 130 
2.5 In vitro Digestion of dry-cured ham peptides 131 
Stability of the peptides of Spanish dry-cured ham extract against in vitro gastric 132 
proteases was assessed using pepsin and pancreatin according to the method of Laparra, 133 
Vélez, Montoro, Barberá and Farré (2003) with some modifications. Pepsin solution in 134 
6 M HCl (pH 2.0) was added to dry-cured ham extract at a 1:100 enzyme to substrate 135 
ratio. After 2 h of digestion at 37 ºC and continuous stirring, the enzyme was inactivated 136 
by adjusting the pH to 7.2 with 1 M NaHCO3. Then, pancreatin was added at a 1:50 137 
enzyme to substrate ratio. After 3 h of digestion at 37 ºC, enzyme activity was 138 
terminated by heating for 10 min at 95 ºC. The reaction mixture was freeze-dried and 139 
then reconstituted for ACE inhibitory activity determination. 140 
 141 
 142 
2.6 Peptide identification by mass spectrometry in tandem (nESI-LC-MS/MS) 143 
The nanoLC-MS/MS analysis was performed using an Eksigent Nano-LC Ultra 1D Plus 144 
system (Eksigent of AB Sciex, CA, USA) coupled to the quadrupole-time-of-flight (Q-145 
ToF) TripleTOF® 5600+ system from AB Sciex Instruments (Framingham, MA, USA) 146 
that is equipped with a nanoelectrospray ionization source. 147 
Desalted dry-cured ham extracts were resuspended in H2O with 0.1% of trifluoroacetic 148 
acid (TFA) to obtain a final concentration of 10 mg/mL. After centrifuge in cold for 3 149 
min at 200xg, fifteen microlitres of each sample (control, processed dry-cured ham 150 
extract, and processed and digested dry-cured ham extract) were cleaned and 151 
concentrated using Zip-Tip C18 with standard bed format (Millipore Corporation, 152 
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Bedford, MA) according to manufacturer’s instructions. Five microlitres of the 153 
supernatant were injected into the LC-MS system through the autosampler. 154 
Samples were then preconcentrated on an Eksigent C18 trap column (3, 350m x 155 
0.5mm) (Eksigent of AB Sciex, CA, USA), at a flow rate of 3 µL/min and using 0.1% 156 
v/v TFA as mobile phase. After 5 min of preconcentration, the trap column was 157 
automatically switched in-line onto a nano-HPLC capillary column (3µm, 75µm x 12.3 158 
cm, C18) (Nikkyo Technos Co, Ltd. Japan). The mobile phases consisted of solvent A, 159 
containing 0.1% v/v formic acid in water, and solvent B, containing 0.1% v/v FA in 160 
100% acetonitrile. Chromatographic conditions were a linear gradient from 5% to 35% 161 
of solvent B over 90 min, and 10 min from 35% to 65% of solvent B, at a flow rate of 162 
0.3 μL/min and running temperature of 30 ºC. 163 
The outlet of the capillary column was directly coupled to a nano-electrospray 164 
ionisation system (nano-ESI). The Q/ToF was operated in positive polarity and 165 
information-dependent acquisition mode, in which a 0.25-s ToF MS scan from m/z of 166 
100 to 1200 was performed, followed by 0.05-s product ion scans from m/z of 100 to 167 
1500 on the 50 most intense 1 to 5 charged ions.  168 
2.7 Data analysis 169 
Automated spectral processing, peak list generation, and database search were 170 
performed using Mascot Distiller v2.4.2.0 software (Matrix Science, Inc., Boston, MA) 171 
(hppt://www.matrixscience.com). The identification of protein origin of peptides was 172 
done using UniProt protein database, with a significance threshold p<0.1 and a FDR of 173 
1.5%. The tolerance on the mass measurement was 0.3 Da in MS mode and 0.3 Da for 174 
MS/MS ions. BIOPEP database was used in the search of similar sequences previously 175 
identified showing ACE inhibitory activity 176 
(http://www.uwm.edu.pl/biochemia/index.php/pl/biopep). 177 
 8 
2.8 Peptide Synthesis  178 
Considering the low molecular mass and the structural requirements for ACE inhibition, 179 
some of the peptides identified from control sample, processed sample at 117 ºC during 180 
6 min, and processed and further in vitro digested sample, were synthesized by 181 
GenScript Corporation (Piscataway, NJ, USA) in order to assess their in vitro inhibition 182 
of ACE. The purity of the synthesized peptides was certified by analytical LC-MS. 183 
3. Results and discussion 184 
3.1 ACE inhibitory activity of Spanish dry-cured ham extract 185 
Bioactive peptides can be found in intact food molecule but they are generally inactive 186 
within the sequence of protein molecule. During the processing of Spanish dry-cured 187 
ham an intense proteolysis takes place resulting in an accumulation of peptides of 188 
different sizes (mainly small peptides) (Mora, Sentandreu, Koistinen, Fraser, Toldrá & 189 
Bramley, 2009; Mora, Sentandreu, Fraser, Toldrá & Bramley, 2009) and free amino 190 
acids at the end of dry-curing (Toldrá, Aristoy & Flores, 2000 ). In previous studies it 191 
was found that peptide fractions from dry-cured ham exhibited relevant ACE inhibitory 192 
activity and in vivo antihypertensive activity (Escudero et al., 2012; Escudero et al., 193 
2013).  194 
Spanish dry-cured ham extract (control sample) was analyzed at different concentrations 195 
in order to get information about ACE inhibitory activity exerted (Fig.1) and select the 196 
most convenient concentration for the stability assays. As can be observed in figure 1, 197 
the extract showed inhibitory activity against ACE at all the assayed concentrations 198 
having a maximum activity of 60.7% at 10 mg/mL. For subsequent experiments the 199 
concentration of 5 mg/mL was chosen due to its proximity to the maximum ACE 200 
inhibitory activity and thus better elucidate the effect of temperature, time, and in vitro 201 
digestion on the bioactivity of the peptidic extract. 202 
 9 
3.2 Impact of temperature and time on the activity of ACE inhibitory peptides 203 
The bioactive peptides derived from Spanish dry-cured ham extract can be directly 204 
ingested from dry-cured ham, either raw or heat treated, or incorporated into other meat 205 
processed products. In this case, it is necessary to consider the stability of the ACE 206 
inhibitory activity among the typical temperature and time processing conditions. The 207 
temperature changes of the extracts were conducted by heating at 50, 72, 90 and 117 ºC 208 
for 6 min (Fig. 2a) and the effect of time was assayed at 117 ºC during 3, 6, 15, 30 and 209 
60 min (Fig. 2b). These temperatures and times are commonly used in the food industry 210 
when processing meat products such as spreadable meat or ham-derived products. As 211 
shown in Fig. 2a and 2b, these peptides retained ACE inhibitory activity after applying 212 
different combinations of temperature and time of processing, which indicates that dry-213 
cured ham ACE inhibitory peptides have good stability against heating. These results 214 
are consistent with those found in ACE inhibitory peptides derived from tuna cooking 215 
juice which exhibited good resistance to different temperatures (20-100ºC for 2 h) 216 
reserving almost the same composition before and after treatments (Hwang, 2010). 217 
Furthermore, peptides derived from soy-protein were also stable after incubating at 218 
different temperatures (20- 100ºC for 2h)  (Wu & Ding, 2002). 219 
3.3 Effect of gastric enzymes on ACE inhibitory activity of dry-cured ham peptides 220 
Digestion is one of the most important processes to release bioactive peptides which are 221 
inactive within the intact protein. Proteolytic enzymes can generate bioactive peptides 222 
during digestion (Hartman et al., 2007; Korhonen & Pihlanto, 2006; Escudero et al., 223 
2010; Escudero, Sentandreu, Arihara & Toldrá, 2010). ACE inhibitory peptides could 224 
exert in vivo antihypertensive effect if they reach the cardiovascular system in an active 225 
form (Vermeirsssen, Van der Bent, Van Camp, Van Amerongen & Verstraete, 2004). 226 
So, after oral administration, peptides need to resist complete degradation by 227 
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gastrointestinal proteases and brush border peptidases, and they have to be absorbed 228 
through the intestinal wall with preservation of their biological activity. During this 229 
process, peptides can be degraded, resulting in an activation or inactivation of their 230 
biological activity. The ACE inhibitory activity of processed sample (117 ºC during 6 231 
min) and further digested by gastric proteases showed little change after in vitro 232 
incubation (Table 1) suggesting that peptides present in processed Spanish dry-cured 233 
ham extract may be resistant to digestion in the gastrointestinal tract or they may be 234 
partially degraded into smaller peptides keeping the antihypertensive biological activity. 235 
Previous reports have shown that small peptides still presented ACE inhibitory activity 236 
after digestion (Hwang, 2010; Wu & Ding, 2002; Jang, Cheorun & Lee, 2007). These 237 
results indicated that orally administered ACE inhibitory peptides could either keep 238 
their sequence integrity in the stomach or break into new smaller bioactive peptides that 239 
could reach the blood stream. 240 
3.4 Identification and synthesis of ACE inhibitory peptides by tandem mass 241 
spectrometry 242 
The desalted dry-cured ham sample used as control, the processed sample (117 ºC 243 
during 6 min), and the same processed and subsequently in vitro digested sample, were 244 
analysed by nanoESI-LC-MS/MS mass spectrometry for the identification of their 245 
peptides content. Fig. 3 shows the total ion chromatograms (TICs) obtained after nano-246 
liquid chromatography in the mass spectrometry system for control sample, processed 247 
sample at 117 ºC for 6 min, and processed and subsequently in vitro digested sample. In 248 
the control and processed sample it can be observed an intensity of peaks very similar 249 
and, as the time progresses, the intensity of peaks decreases. On the other hand, in the 250 
processed and further digested sample it can be observed, in general, a decrease in the 251 
intensity of the detected ions, possibly because of changes in the characteristics of 252 
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peptides after digestion. Biological activities of peptides are related to their amino acid 253 
composition, sequence, size, and configuration (Matsui & Matsumoto, 2006). Most food 254 
protein-derived peptides with ACE inhibitory activity have low molecular mass, 255 
generally ranging from dipeptides to pentapeptides with molecular masses between 150 256 
and 800 Da (Zhang, Wang & Wu, 2009). In this respect, the synthesised peptides had 257 
molecular mass <600 Da and contained between 5 and 7 amino acids. Considering the 258 
low molecular mass and structural requirements for ACE inhibition, some of the 259 
identified peptides were synthesised and their IC50 calculated. Table 2 shows the 260 
sequence of the identified and synthesised peptides, the observed and calculated masses 261 
together with the charge states, and the protein of origin. So, six and seven of the 262 
peptides chosen for synthesis derive from myosin and titin proteins, respectively, 263 
whereas only four come from other type of proteins. The abundance of peptides derived 264 
from these proteins is due to the abundance of myosin and titin in skeletal muscle, and 265 
proves the high level of hydrolysis occurred during the dry-cured processing (Mora, 266 
Sentandreu, Koistinen, Fraser, Toldrá, and Bramley, 2009) as well as confirms that 267 
these proteins constitute a good source of ACE inhibitory peptides (Escudero et al, 268 
2010). 269 
All peptides share sequence with previously identified protein fragments that have been 270 
described as ACE inhibitors as shown in Table 2. In previous studies it has been 271 
reported that binding to ACE was strongly influenced by the residues at the three 272 
positions closest to the C-terminal site, especially hydrophobic amino acids as proline 273 
(Rohrbach, Willians, Rolsad, 1981) which is the most favourable C-terminal amino acid 274 
for binding to ACE. Also, the amino acid alanine close to the C-terminal position might 275 
also positively influence the binding to ACE (Majumder & Wu, 2009). In fact, best 276 
ACE inhibitory results in this study have been obtained for peptides KAAAAP, 277 
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AAPLAP, KPVAAP, IAGRP, and KAAAATP, with IC50 values of 19.79, 14.38, 12.37, 278 
25.94, and 25.64 M, respectively, with an alanine and proline residue close to C-279 
terminal and in the last C-terminal position, respectively. The activities of these novel 280 
peptides were extraordinarily higher than those previously identified from pork meat 281 
hydrolysates (Arihara, Nakashima, Mukai, Ishikawa & Itoh, 2001; Katayama et al., 282 
2008) 283 
Peptide IAGRP has been identified by MS/MS in the control, the sample processed 284 
during 6 min at 117 ºC, and in the processed extract after in vitro digestion with pepsin 285 
and pancreatin enzymes, proving the stability of this antihypertensive peptide after 286 
processing and digestion. Also the identity of peptide PTPVP has been confirmed in the 287 
control, the processed sample, and in the sample after in vitro digestion. This peptide 288 
has been previously identified and tested in vitro for its ACE inhibitory activity after a 289 
simulated gastrointestinal digestion of pork meat, showing an IC50 of 256.41 M (see 290 
Table 2) (Escudero et al., 2010). More recently, the in vivo antihypertensive activity of 291 
PTPVP has been tested in spontaneously hypertensive rats (SHRs), resulting in a 292 
decrease of the systolic blood pressure of 24.52 mmHg (p<0.01) and 25.66 mmHg 293 
(p<0.01) at 4 and 6 h after single oral administration, respectively (Escudero et al., 294 
2012). On the other hand, the synthesised peptide KAAAATP has shown an IC50 value of 295 
25.64 M in this study (see Table 2). The fragment AAATP was also previously 296 
identified in a Spanish dry-cured ham and gave an IC50 value of 100 M (Escudero et 297 
al., 2013). These results are in agreement with the obtained results in this study. 298 
The processing of dry-cured ham extract under extreme conditions of temperature and 299 
time as well as the in vitro digestion with pepsin and pancreatin enzymes, could be the 300 
responsible for the degradation of some of the ACE inhibitory peptides identified in the 301 
control extract. Despite this situation, the ACE inhibitory activity remained constant 302 
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after processing and digestion, probably due to the presence of the tripeptide fragments 303 
described in Table 2, which have been previously proved to be good antihypertensive 304 
peptides. This fact could not be confirmed because the conditions of mass spectrometry 305 
and data analysis tools used in this study does not allow the identification of di- and 306 
tripeptides as their small size makes them difficult to be fragmented in the analysers, 307 
and their short sequence decrease the possibility to find a specific origin protein as the 308 
possibilities to be present in different sequences of Sus scrofa proteome increase with 309 
the shortness of the peptide. 310 
4. Conclusion  311 
According to this study, the bioactivity of ACE inhibitory peptides was not affected by 312 
heat treatments and they still showed relevant ACE inhibitory activity after in vitro 313 
digestion by gastrointestinal proteases. A total of 16 peptides identified in the control 314 
sample were synthesised and their IC50 calculated being KAAAAP, AAPLAP, KPVAAP, 315 
IAGRP, and KAAAATP the most active peptides presenting IC50 values ranging from 316 
12.37 M to 25.94 M. Peptide IAGRP has also been identified in the processed 317 
sample during 6 min at 117 ºC, and in the processed and further in vitro digested sample. 318 
Also, peptide PTPVP that has been previously described by Escudero et al. (2010; 319 
2012) was identified in the control, processed sample, and processed and digested 320 
sample. These findings prove the stability of ACE inhibitory activity of peptides 321 
submitted to intense processing conditions and after digestion. ACE inhibitory activity 322 
keeps constant probably due to the presence of the identified antihypertensive peptides 323 
as well as small fragments resulting from their degradation occurred after processing 324 
and in vitro digestion.  325 
The knowledge of interactions of bioactive peptides with other food components during 326 
processing and the evaluation of efficacy of bioactive peptides in animal model and 327 
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human clinical studies per se and in food systems will be crucial to ensure activity and 328 
bioavailability of these bioactive peptides. 329 
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LEGENDS FOR THE FIGURES 489 
Figure 1. ACE inhibitory (ACEI) activity of Spanish dry-cured ham extract (control) at 490 
different concentrations. 491 
Figure 2. Stability of Spanish dry-cured ham-derived ACE inhibitory peptides after: a) 492 
6 min incubation at various temperatures, and b) 117ºC incubation at different times. 493 
The relative ACE inhibitory percent was calculated as the ratio of ACE inhibitory 494 
activity between the control and treatments. Bars represent means ± SD. 495 
 18 
Figure 3. Total ion chromatograms (TICs) obtained after nano-liquid chromatography 496 
in the mass spectrometry system for control sample, processed sample at 117 ºC for 6 497 
min, and processed and subsequently in vitro digested sample. 498 
 499 
 500 
 501 
 502 
Lines were numbered 5 to 5 and are now numbered consecutively 1 by 1. 
Responses to Technical Check Results
 Table 1. Activity of the Spanish dry-cured ham extract following processing (117 ºC 
during 6 min), and processing and further in vitro digestion by gastrointestinal 
proteases. 
      
Sample ACE inhibition (%) CV (%) 
Control 45.9±1.115 2.42 
Processed sample 40.42±0.54 1.33 
Processed + digested sample 42.01±3.44 8.18 
All values are mean±standard deviation for triplicate experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table(s)
  
Table 2. Peptides from the desalted dry-cured ham extract (control sample) identified 
by nanoESI-LC-MS/MS and synthesised to test the ACE inhibitory activity. 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide P0
a
Sequence Pf
b Observed
c
Charge Calculated
d
Protein of origin
Number (m/z ) (H
+
) Mr
1 A PAPPK
ф
E 509.30 1 508.30 Myosin light chain 1/3
2 A KAAAAP A 528.27 1 527.31 Myosin light chain 3
3 Y AMNPP K 545.25 1 544.23 Myosin-3
4 N IKLPP G 567.59 1 566.38 Myosin-IXb 
5 A AAPLAP I 539.34 1 538.31 Myosin-XV
6 I KPVAAP V 582.29 1 581.35 Myosin-XV 
7 A VPPAK G 511.47 1 510.32 Titin 
8 D KPGRP D 554.27 1 553.33 Titin 
9 P PSNPP E 511.47 1 510.24 Titin 
10 D IAGRP* L 257.18 2 512.31 Titin 
11 P EAPPK R 541.27 1 540.29 Titin 
12 R PAAPPK K 580.25 1 579.34 Titin 
13 G KVLPG V 257.19 2 512.33 Phosphoglycerate kinase 1 
14 F TGLKP E 515.26 1 514.31 Aspartate aminotransferase
15 P AAATPL
¥
A 272.22 2 542.31 Epithelial splicing regulatory protein 2 
16 V KAAAATP F 629.30 1 628.35 PR domain zinc finger protein 2 
17 K PTPVP* K 510.25 1 509.29 Titin
a. Amino acid residue preceding the peptide sequence; b. amino acid residue following the peptide sequence; c. Relation of
mass/charge (m/z ) observed in the nanoLC-MS/MS system; d. Calculated relative molecular mass in Daltons of the matched
peptide; ф Peptide PAPPK has been also identified in the extract processed at 117oC during 5 min; * Peptides IAGRP and
PTPVP have been identified in the processed extract at 117oC during 5 min and after digestion. PTPVP peptide was synthesized
and tested in vitro and in vivo in a previous work as indicated in Table 2; ¥ Peptide AAATPL has been identified in the processed
extract after digestion.
  
Table 3. ACE inhibitory activity (IC50) of synthesised peptides and previously 
published ACE inhibitory fragments of these peptides. 
 
 
 
 
 
 
 
 
Peptide Sequence IC50
Number Identified (mM) Sequence IC50
b
(mM) References
c
1 PAPPK 199.58 PPK >1000 Meisel H., Walsh D. J., Murray B. & Fitzgerald R. J. (2006); 
n.d. Hayes M., Stanton C., Fitzgerald G.F. & Ross R.P. (2007)
2 KAAAAP 19.79 AAP n.d. Meisel H. (1993)
3 AMNPP 304.50 MNPP 945.5 Arihara K.,Nakashima Y., Mukai T., Ishikawa S. & Itoh M. (2001)
4 IKLPP 193.90 LPP 9.6 Maruyama S., Miyoshi S., Kaneko T. & Tanaka H. (1989)
5 AAPLAP 14.38 LAP 3.5 Fujita H., Yokoyama K. & Yoshikawa M. (2000)
6 KPVAAP 12.37 AAP n.d. Meisel H. (1993)
7 VPPAK >1000 VPP 9 Nakamura Y., Yamamoto N., Sakai K., Yamazaki S. & Takano T. (1995)
8 KPGRP 67.08 GRP 19.9 Matsufuji H., Matsui T., Seki E., Osajima K., Nakashima M. & Osajima Y. (1994)
9 PSNPP 192.27 NPP 250.9 Arihara K., Nakashima Y., Mukai T., Ishikawa S. & Itoh M. (2001)
10 IAGRP 25.94 GRP 19.9 Matsufuji H., Matsui T., Seki E., Osajima K., Nakashima M. & Osajima Y. (1994)
11 EAPPK >1000 PPK >1000 Meisel H., Walsh D. J., Murray B. & Fitzgerald R. J. (2006); 
n.d. Hayes M., Stanton C., Fitzgerald G.F. & Ross R.P. (2007)
12 PAAPPK >1000 PPK >1000 Meisel H., Walsh D. J., Murray B. & Fitzgerald R. J. (2006); 
n.d. Hayes M., Stanton C., Fitzgerald G.F. & Ross R.P. (2007)
13 KVLPG 265.44 LPG 5.73 Byun H.-G. & Kim S.-K. (2002)
14 TGLKP 51.57 LKP 0.32 Fujita H., Yokoyama K. & Yoshikawa M. (2000)
15 AAATPL n.d. AAATP 100 Escudero E., Mora, L., Fraser P.D., Aristoy M.C., Arihara K. & Toldrá F. (2013)
16 KAAAATP 25.64 AAATP 100 Escudero E., Mora, L., Fraser P.D., Aristoy M.C., Arihara K. & Toldrá F. (2013)
17 PTPVP* PTPVP 256.41 Escudero E., Sentandreu M. A., Arihara K. & Toldrá F. (2010)
Previously identified ACE inhibitory sequences
a
a. ACE inhibitory sequences previously identified that share amino acid residues with the sequences identified in this work.; b. IC50 of the fragments
previously published.; * PTPVP peptide was synthesized and tested in vitro  and in vivo  in a previous work.; n.d. means non-detected.
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